Altimmune, Inc. (ALT) Financial Statements (2024 and earlier)

Company Profile

Business Address 910 CLOPPER ROAD
GAITHERSBURG, MD 20878
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments159,954165,729184,880201,827184,756179,947
Cash and cash equivalents102,352104,690111,097127,465135,858179,947
Short-term investments57,60261,03973,78374,36248,898 
Restricted cash and investments413434343434
Receivables136252173633195193
Other undisclosed current assets9,4017,0967,7268,51010,51910,919
Total current assets:169,532173,111192,813211,004195,504191,093
Noncurrent Assets
Property, plant and equipment8821,0071,0811,1721,2361,337
Intangible assets, net (including goodwill)12,41912,41912,41912,41912,41912,419
Intangible assets, net (excluding goodwill)12,41912,41912,41912,41912,41912,419
Other noncurrent assets483546615682747811
Total noncurrent assets:13,78413,97214,11514,27314,40214,567
TOTAL ASSETS:183,316187,083206,928225,277209,906205,660
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,0466,5378,0355,3225,0703,964
Taxes payable1,169
Employee-related liabilities2,1101,4931,117
Accounts payable4,0355,2384,8041,4192,8722,205
Accrued liabilities2,0111,2993,231624705642
Business combination, contingent consideration, liability      4,310
Other undisclosed current liabilities5,3918,4149,01910,4208,77510,850
Total current liabilities:11,43714,95117,05415,74213,84519,124
Noncurrent Liabilities
Long-term debt and lease obligation4,1654,4004,5814,5061,5261,668
Long-term debt, excluding current maturities4,1654,4004,5814,5061,5261,668
Total noncurrent liabilities:4,1654,4004,5814,5061,5261,668
Total liabilities:15,60219,35121,63520,24815,37120,792
Equity
Equity, attributable to parent167,714167,732185,293205,029194,535184,868
Common stock555554
Additional paid in capital586,908570,786568,399566,551532,398502,505
Accumulated other comprehensive loss(5,180)(5,101)(5,227)(5,303)(5,160)(5,040)
Accumulated deficit(414,019)(397,958)(377,884)(356,224)(332,708)(312,601)
Total equity:167,714167,732185,293205,029194,535184,868
TOTAL LIABILITIES AND EQUITY:183,316187,083206,928225,277209,906205,660

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues621(110)2832
Gross profit:621(110)2832
Operating expenses(18,013)(21,780)(22,984)(24,754)(20,403)(19,531)
Operating loss:(18,007)(21,759)(23,094)(24,752)(20,395)(19,499)
Nonoperating income1,9461,6851,4341,03928869
Investment income, nonoperating1,8351,6681,4681,05332821
Other nonoperating income (expense)11319(217)5025110
Interest and debt expense(2)(2)183(64)(65)(62)
Loss from continuing operations before equity method investments, income taxes:(16,063)(20,076)(21,477)(23,777)(20,172)(19,492)
Other undisclosed income (loss) from continuing operations before income taxes  (183)64  
Loss from continuing operations before income taxes:(16,063)(20,076)(21,660)(23,713)(20,172)(19,492)
Income tax benefit    197  
Loss from continuing operations:(16,063)(20,076)(21,660)(23,516)(20,172)(19,492)
Loss before gain (loss) on sale of properties:(23,516)(20,172)(19,492)
Other undisclosed net income  2   62
Net loss:(16,063)(20,074)(21,660)(23,516)(20,172)(19,430)
Other undisclosed net income attributable to parent 2   65 
Net loss available to common stockholders, diluted:(16,061)(20,074)(21,660)(23,516)(20,107)(19,430)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(16,063)(20,074)(21,660)(23,516)(20,172)(19,430)
Other undisclosed comprehensive income (loss)(77)12676(143)(55) 
Comprehensive loss, net of tax, attributable to parent:(16,140)(19,948)(21,584)(23,659)(20,227)(19,430)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: